{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:58:07Z","timestamp":1785427087785,"version":"3.56.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Invasive fungal infections (IFIs) are a rising problem among pediatric patients. Antifungal agents have data supporting treatment in pediatric patients of varying ages and infection types but in vitro susceptibility data for large collections of pediatric isolates are lacking, which limits empiric treatment. We describe in vitro antifungal susceptibility testing of 900 contemporary yeast and mold isolates collected from IFIs in patients \u2264 17\u00a0years of age as a part of the SENTRY Antifungal Surveillance Program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 900 isolates (743 yeasts and 157 molds) were collected from 28 countries between 2017 and 2024. Antifungal susceptibility testing was performed by broth microdilution according to Clinical and Laboratory and Standards Institute (CLSI) methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 33.4% of isolates were from patients \u2264 1\u00a0year old, 22.1% from patients aged 2-5 years old, 24.4% from patients aged 6-12\u00a0years old, and 20.0% from patients aged 13-17\u00a0years old. In total, 63.0% of yeasts were recovered from patients \u2264 5\u00a0years old; 79.6% of molds were from patients \u2265 6\u00a0years old. Most yeast isolates (72.5%) were from bloodstream infections; most mold isolates (61.8%) were from the respiratory tract. By CLSI breakpoints, 88.5% and 87.5% of Aspergillus fumigatus isolates were susceptible to voriconazole and isavuconazole, respectively. Against Mucorales, the isavuconazole minimum inhibitory concentration (MIC)50 value was 4\u00a0mg\/L, whereas the MIC50 values for voriconazole and posaconazole were\u2009&amp;gt;\u20098\u00a0mg\/L. All agents had low MICs against most yeasts collected and there were few resistant or non-wildtype yeasts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Broth microdilution among a diverse collection of isolates obtained from IFIs among pediatric patients showed low rates of resistance to echinocandins or azoles. Across species, the lowest MICs were observed for voriconazole and isavuconazole in yeasts. All triazoles were highly active against Aspergillus spp. Against non-Aspergillus molds, isavuconazole, posaconazole, and amphotericin B were the most active agents. These data can guide the antifungal treatment of IFIs in pediatric patients when susceptibility testing is unavailable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpids\/piag053","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:56:34Z","timestamp":1783511794000},"source":"Crossref","is-referenced-by-count":0,"title":["Activity of Isavuconazole and Comparator Agents Against Pediatric Isolates From Invasive Fungal Infections"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9785-5034","authenticated-orcid":false,"given":"Marisa L","family":"Winkler","sequence":"first","affiliation":[{"name":"Element Iowa City (JMI Laboratories) , North Liberty, IA 52317 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories) , North Liberty, IA 52317 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Fedler","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories) , North Liberty, IA 52317 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Edeker","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories) , North Liberty, IA 52317 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby L","family":"Klauer","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories) , North Liberty, IA 52317 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories) , North Liberty, IA 52317 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2026073011020266400_ref1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1469-0691.2009.02909.x","article-title":"Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues","volume":"15","author":"Arendrup","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"2026073011020266400_ref2","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"2026073011020266400_ref3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/01.inf.0000078159.53132.40","article-title":"Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities","volume":"22","author":"Wisplinghoff","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2026073011020266400_ref4","first-page":"3","article-title":"Pediatric liver transplant recipients: mortality analysis over 20 years","volume":"38","author":"Profumo","year":"2006","journal-title":"J Insur Med"},{"key":"2026073011020266400_ref5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/jpids\/pix107","article-title":"Mucormycosis in children: review and recommendations for management","volume":"7","author":"Francis","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2026073011020266400_ref6","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2023-9-2","article-title":"Invasive fungal infections in critically ill children: epidemiology, risk factors and antifungal drugs","volume":"13","author":"Hon","year":"2024","journal-title":"Drugs Context"},{"key":"2026073011020266400_ref7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/jpids\/piz007","article-title":"Pediatric mucormycosis: a 10-year systematic review of reported cases and review of the literature","volume":"8","author":"Otto","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2026073011020266400_ref8","year":"2023"},{"key":"2026073011020266400_ref9","year":"2024"},{"key":"2026073011020266400_ref10","doi-asserted-by":"publisher","first-page":"e0048424","DOI":"10.1128\/aac.00484-24","article-title":"Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial","volume":"68","author":"Segers","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026073011020266400_ref11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01230-18","article-title":"In vitro activity of Isavuconazole against opportunistic fungal pathogens from two mycology reference laboratories","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026073011020266400_ref12","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2017","edition":"4"},{"key":"2026073011020266400_ref13","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibilty Testing of Filamentous Fungi","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2017","edition":"3"},{"key":"2026073011020266400_ref14","volume-title":"Performance Standards for Antifungal Susceptibility Testing of Yeasts","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2022","edition":"3"},{"key":"2026073011020266400_ref15","volume-title":"Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2022","edition":"3"},{"key":"2026073011020266400_ref16","volume-title":"Epidemiological Cutoff Values for Antifungal Susceptibility Testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2022","edition":"4"},{"key":"2026073011020266400_ref17","volume-title":"Isavuconazole Breakpoints for Aspergillus fumigatus","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2025"},{"key":"2026073011020266400_ref18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/myc.13267","article-title":"Isavuconazole nonwildtype aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles","volume":"64","author":"Castanheira","year":"2021","journal-title":"Mycoses"},{"key":"2026073011020266400_ref19","doi-asserted-by":"publisher","first-page":"e0114123","DOI":"10.1128\/jcm.01141-23","article-title":"Trends in the activity of mold-active azole agents against aspergillus fumigatus clinical isolates with and without cyp51 alterations from Europe and North America (2017-2021)","volume":"62","author":"Pfaller","year":"2024","journal-title":"J Clin Microbiol"},{"key":"2026073011020266400_ref20","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1128\/AAC.01711-09","article-title":"Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains","volume":"54","author":"Castanheira","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026073011020266400_ref21","doi-asserted-by":"publisher","first-page":"e0244921","DOI":"10.1128\/jcm.02449-21","article-title":"Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020)","volume":"60","author":"Carvalhaes","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2026073011020266400_ref22","volume-title":"M38M51S Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2026"},{"key":"2026073011020266400_ref23","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1128\/JCM.05474-11","article-title":"Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey","volume":"49","author":"Peman","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2026073011020266400_ref24","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/JCM.40.3.852-856.2002","article-title":"Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000","volume":"40","author":"Pfaller","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2026073011020266400_ref25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2026073011020266400_ref26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/INF.0b013e31824da7fe","article-title":"Epidemiology, risk factors and outcome of Candida parapsilosis bloodstream infection in children","volume":"31","author":"Dotis","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2026073011020266400_ref27","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1086\/520277","article-title":"Emergence of Candida parapsilosis as the predominant species causing candidemia in children","volume":"26","author":"Levy","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2026073011020266400_ref28","doi-asserted-by":"publisher","DOI":"10.3390\/jof2010005","article-title":"Pediatric invasive candidiasis: epidemiology and diagnosis in children","volume":"2","author":"Steinbach","year":"2016","journal-title":"J Fungi (Basel)"},{"key":"2026073011020266400_ref29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026073011020266400_ref30","doi-asserted-by":"publisher","first-page":"dlab088","DOI":"10.1093\/jacamr\/dlab088","article-title":"Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme","volume":"3","author":"Carvalhaes","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2026073011020266400_ref31","volume-title":"Clinical Breakpoints for Fungi (Candida and Aspergillus Species)","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2020"},{"key":"2026073011020266400_ref32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01916-17","article-title":"Posaconazole MIC distributions for Aspergillus fumigatus species complex by four methods: impact of cyp51A mutations on estimation of epidemiological cutoff values","volume":"62","author":"Espinel-Ingroff","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026073011020266400_ref33","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Espinel-Ingroff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2026073011020266400_ref34","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/jac\/dkae099","article-title":"Posaconazole in paediatric malignancy and haematopoietic stem cell transplant: dosing to achieve therapeutic concentration","volume":"79","author":"Weerdenburg","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026073011020266400_ref35","doi-asserted-by":"publisher","first-page":"e0029021","DOI":"10.1128\/AAC.00290-21","article-title":"Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients","volume":"65","author":"Arrieta","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026073011020266400_ref36","doi-asserted-by":"publisher","first-page":"106084","DOI":"10.1016\/j.ijantimicag.2020.106084","article-title":"Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial","volume":"56","author":"Groll","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2026073011020266400_ref37","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026073011020266400_ref38","volume-title":"Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV","author":"Panel on Opportunistic Infections in Children With and Exposed to HIV","year":"2026"},{"key":"2026073011020266400_ref39","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026073011020266400_ref40","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026073011020266400_ref41","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson Gr","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piag053\/68740542\/piag053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/15\/7\/piag053\/68740542\/piag053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/15\/7\/piag053\/68740542\/piag053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:02:13Z","timestamp":1785423733000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piag053\/8729274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piag053","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"piag053"}}